

02-33000-33

Original Effective Date: 08/15/13

Reviewed: 07/25/24

Revised: 08/15/24

Subject: Transcatheter Pulmonary Valve Implantation

THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS, OR A GUARANTEE OF PAYMENT, NOR DOES IT SUBSTITUTE FOR OR CONSTITUTE MEDICAL ADVICE. ALL MEDICAL DECISIONS ARE SOLELY THE RESPONSIBILITY OF THE PATIENT AND PHYSICIAN. BENEFITS ARE DETERMINED BY THE GROUP CONTRACT, MEMBER BENEFIT BOOKLET, AND/OR INDIVIDUAL SUBSCRIBER CERTIFICATE IN EFFECT AT THE TIME SERVICES WERE RENDERED. THIS MEDICAL COVERAGE GUIDELINE APPLIES TO ALL LINES OF BUSINESS UNLESS OTHERWISE NOTED IN THE PROGRAM EXCEPTIONS SECTION.

[Position Statement](#)

[Billing/Coding](#)

[Reimbursement](#)

[Program Exceptions](#)

[Definitions](#)

[Related Guidelines](#)

[Other](#)

[References](#)

[Updates](#)

DESCRIPTION:

Transcatheter pulmonary valve implantation (TPVI) has been proposed as a less invasive alternative to open surgical pulmonary valve replacement or reconstruction for right ventricular outflow tract (RVOT) obstruction. Percutaneous pulmonary valve replacement may be indicated for congenital pulmonary stenosis. Pulmonary stenosis or regurgitation in a patient with congenital heart disease (CHD) who has previously undergone RVOT surgery is additional indications. Patients with prior CHD repair are at risk of needing repeated reconstruction procedures.

Several transcatheter pulmonary valve device systems have received FDA approval (e.g., Melody Transcatheter Pulmonary Valve (TPV) and the Ensemble Transcatheter Valve Delivery System, Edwards SAPIEN XT Transcatheter Heart Valve (THV) Systems).

Summary and Analysis of Evidence: Sinha et al (2019) Patients with dysfunctional right ventricular outflow tracks comprise a large portion of patients with severe congenital heart disease. Transcatheter pulmonary valve replacement in patients with dysfunctional right ventricular outflow tracks is feasible, safe, and efficacious.

Cheatman et al (2015) Studies of transcatheter pulmonary valve (TPV) replacement with the Melody valve have demonstrated good short-term outcomes. TPV replacement with the Melody valve provided good hemodynamic and clinical outcomes up to 7 years after implantation.

Balzer et al (2019) Right ventricular outflow tract (RVOT) dysfunction is common following surgical repair of tetralogy of Fallot and other forms of complex congenital heart disease. This results in pulmonary stenosis or regurgitation and may ultimately lead to right ventricular (RV) failure and dysrhythmias. Transcatheter valve technologies are now available to treat certain patients with RVOT dysfunction. Current devices include the Medtronic Melody valve and the Edwards Lifesciences SAPIEN

XT. Although these valves are approved for use in dysfunctional circumferential RVOT conduits, they are increasingly being used off label for nonconduit outflow tracts. Procedural complications include but are not limited to conduit rupture and coronary compression. Longer-term complications include stent fracture and endocarditis. Outcomes with these valves have demonstrated durable relief of stenosis and regurgitation.

POSITION STATEMENT:

Transcatheter pulmonary valve implantation using a Food and Drug Administration (FDA) device **meets the definition of medical necessity** for members with congenital heart disease and current right ventricular outflow tract obstruction (RVOT) or regurgitation for the following indications:

- Members with right ventricle-to-pulmonary artery conduit with or without bioprosthetic valve with at least moderate pulmonic regurgitation; **OR**
- Members with native or patched RVOT with at least moderate pulmonic regurgitation; **OR**
- Members with right ventricle-to-pulmonary artery conduit with or without bioprosthetic valve with pulmonic stenosis (mean RVOT gradient at least 35 mm Hg); **OR**
- Members with native or patched RVOT with pulmonic stenosis (mean RVOT gradient at least 35 mm Hg).

The Melody transcatheter pulmonary valve and the Ensemble Transcatheter Valve Delivery System **meets the definition of medical necessity** as an adjunct to surgery in the management of pediatric and adult members with the following clinical conditions:

1. Existence of a full (circumferential) RVOT conduit that was equal to or greater than 16 mm in diameter when originally implanted, **AND**
2. Dysfunctional RVOT conduits with clinical indication for intervention, and either:
 - a. Regurgitation: \geq moderate regurgitation, **OR**
 - b. Stenosis: mean RVOT gradient \geq 35 mm Hg

Transcatheter pulmonary valve implantation is considered **experimental or investigational** for all other indications. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

BILLING/CODING INFORMATION:

CPT Coding

33477	Transcatheter pulmonary valve implantation, percutaneous approach, including pre-stenting of the valve delivery site, when performed
-------	--

REIMBURSEMENT INFORMATION:

Refer to section entitled [POSITION STATEMENT](#).

PROGRAM EXCEPTIONS:

Federal Employee Program (FEP): Follow FEP guidelines.

State Account Organization (SAO): Follow SAO guidelines.

Medicare Advantage products: No Local Coverage Determination (LCD) and/or National Coverage Determinations (NCD) was found at the time of the last guideline reviewed date.

If this Medical Coverage Guideline contains a step therapy requirement, in compliance with Florida law 627.42393, members or providers may request a step therapy protocol exemption to this requirement if based on medical necessity. The process for requesting a protocol exemption can be found at [Coverage Protocol Exemption Request](#).

DEFINITIONS:

No guideline specific definitions apply.

RELATED GUIDELINES:

[Transcatheter Aortic Valve Replacement, 02-33000-32](#)

OTHER:

Other terms used to describe transcatheter pulmonary valve implantation:

Note: The use of specific product names is illustrative only. It is not intended to be a recommendation of one product over another and is not intended to represent a complete listing of all products available.

CoreValve™ System (aortic valve)

Edwards SAPIEN® transcatheter heart valve (aortic valve)

Medtronic Melody (pulmonary valve)

Percutaneous pulmonary valve implantation (PPVI)

Transcatheter pulmonary valve replacement (TPVR)

Harmony™ transcatheter pulmonary valve (TPV)

REFERENCES:

1. Balzer D. Pulmonary Valve Replacement for Tetralogy of Fallot. *Methodist Debaquey Cardiovasc J*. 2019 Apr-Jun;15(2):122-132.
2. Bhatt AB, Foster E, Kuehl K et al. Congenital heart disease in the older adult: a scientific statement from the American Heart Association. *Circulation*. 2015 May; 131(21):1884-1931.
3. Blue Cross Blue Shield Association Evidence Positioning System® 7.01.131 Transcatheter Pulmonary Valve Implantation, 07/24.
4. Boudjemline Y, Malekzadeh-Milani S, Patel M et al. Predictors and outcomes of right ventricular outflow tract conduit rupture during percutaneous pulmonary valve implantation: a multicentre study. *EuroIntervention*. 2016 Jan; 11(9):1053-1062.

5. Chatterjee A, Bajaj NS, McMahon WS et al. Transcatheter pulmonary valve implantation: a comprehensive systematic review and meta-analyses of observational studies. *Journal of the American Heart Association*. 2017 Aug; 6(8). pii: e006432.
6. Cheatham JP, Hellenbrand WE, Zahn EM et al. Clinical and hemodynamic outcomes up to 7 years after transcatheter pulmonary valve replacement in the US melody valve investigational device exemption trial. *Circulation*. 2015 Jun; 131(22):1960-1970.
7. Gillespie M, McElhinney DB, Kreutzer J et al. Transcatheter pulmonary valve replacement for right ventricular outflow tract conduit dysfunction after the Ross procedure. *Annals of Thoracic Surgery*. 2015 Sep; 100(3):996-1002.
8. Gillespie MJ, McElhinney DB, Jones TK, et al. 1-Year Outcomes in a Pooled Cohort of Harmony Transcatheter Pulmonary Valve Clinical Trial Participants. *JACC Cardiovasc Interv*. 2023 Aug 14;16(15):1917-1928.
9. Gillespie MJ, Rome JJ, Levi DS, Williams RJ, Rhodes JF, Cheatham JP, Hellenbrand WE, Jones TK, Vincent JA, Zahn EM, McElhinney DB. Melody valve implant within failed bioprosthetic valves in the pulmonary position: a multicenter experience. *Circ Cardiovasc Interv*. 2012 Dec; 5(6):862-70.
10. Hasan BS, McElhinney DB, Brown DW, Cheatham JP, Vincent JA, Hellenbrand WE, Jones TK, Zahn EM, Lock JE. Short-term performance of the transcatheter Melody valve in high-pressure hemodynamic environments in the pulmonary and systemic circulations. *Circ Cardiovasc Interv*. 2011 Dec;4(6):615-20.
11. Hijazi ZM, Ruiz CE, Zahn E et al. SCAI/AATS/ACC/STS operator and institutional requirements for transcatheter valve repair and replacement, Part III: pulmonic valve. *Journal of the American College of Cardiology*. 2015 Jun; 65(23):2556-2563.
12. Jones TK, McElhinney DB, Vincent JA, et al. Long-Term Outcomes After Melody Transcatheter Pulmonary Valve Replacement in the US Investigational Device Exemption Trial. *Circ Cardiovasc Interv*. 2022 Jan;15(1): e010852.
13. Lopez KN, Baker-Smith C, Flores G, et al. Addressing Social Determinants of Health and Mitigating Health Disparities Across the Lifespan in Congenital Heart Disease: A Scientific Statement from the American Heart Association. *J Am Heart Assoc*. 2022 Apr 19; 11(8): e025358.
14. McElhinney DB, Cabalka AK, Aboulhosn JA et al. Transcatheter Tricuspid Valve-in-Valve Implantation for the Treatment of Dysfunctional Surgical Bioprosthetic Valves: An International, Multicenter Registry Study. *Circulation*. 2016 Apr; 133(16):1582-1593.
15. McElhinney DB, Cheatham JP, Jones TK, Lock JE, Vincent JA, Zahn EM, Hellenbrand WE. Stent fracture, valve dysfunction, and right ventricular outflow tract reintervention after transcatheter pulmonary valve implantation: patient-related and procedural risk factors in the US Melody Valve Trial. *Circ Cardiovasc Interv*. 2011 Dec ;4(6):602-14.
16. McElhinney DB, Hellenbrand WE, Zahn EM, Jones TK, Cheatham JP, Lock JE, Vincent JA. Short- and medium-term outcomes after transcatheter pulmonary valve placement in the expanded multicenter US melody valve trial. *Circulation*. 2010 Aug;122(5):507-16.
17. McElhinney DB, Zhang Y, Aboulhosn JA, et al. Multicenter Study of Endocarditis After Transcatheter Pulmonary Valve Replacement. *J Am Coll Cardiol*. 2021 Aug 10;78(6):575-589.
18. McElhinney DB, Zhang Y, Levi DS, et al. Reintervention and Survival After Transcatheter Pulmonary Valve Replacement. *J Am Coll Cardiol*. 2022 Jan 4;79(1):18-32.
19. National Guideline Clearinghouse. Guideline Summary. Recommendations for delivery of care and ensuring access. In: ACC/AHA 2008 guidelines for the management of adults with congenital heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

20. National Institute for Health and Clinical Excellence (NICE) Interventional Procedure Guidance 436. Percutaneous pulmonary valve implantation for right ventricular outflow tract dysfunction. January 2013.
21. Nishimura RA, Otto CM, Bonow RO et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Journal of the American College of Cardiology*. 2017 Jul; 70(2):252-289.
22. Nishimura RA, Otto CM, Bonow RO et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology*. 2014 Jun; 63(22): e57-185.
23. Sinha S, Aboulhosn J, Levi DS. Transcatheter Pulmonary Valve Replacement in Congenital Heart Disease. *Interv Cardiol Clin*. 2019 Jan;8(1):59-71. [Abstract].
24. Thyregod HG, Søndergaard L, Ihlemann N, Franzen O, Andersen LW, Hansen PB, Olsen PS, Nissen H, Winkel P, Gluud C, Steinbrüchel DA. The Nordic aortic valve intervention (NOTION) trial comparing transcatheter versus surgical valve implantation: study protocol for a randomised controlled trial. *Trials*. 2013 Jan 9; 14:11.
25. Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA, del Nido P, Fasules JW, Graham TP, Hijazi ZM, Hunt SA, King ME, Landzberg MJ, Miner PD, Radford MJ, Walsh EP, Webb GD, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Buller CD, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura RA, Page RL, Riegel B, Tarkington LG, Yancy CW. Recommendations for delivery of care and ensuring access. In: ACC/AHA 2008 guidelines for the management of adults with congenital heart disease. *J Am Coll Cardiol*. 2008; 52(23): e151-73.
26. U.S. Food and Drug Administration. Summary of Safety and Effectiveness Data: Edwards SAPIEN XT™ Transcatheter Heart Valve P130009/S037, February 29, 2016.
27. U.S. Food and Drug Administration. Summary of Safety and Effectiveness Data: Melody™ Transcatheter Pulmonary Valve, models PB1016 and PB1018; Ensemble™ Transcatheter Valve Delivery System February 24, 2017.
28. Webb JG, Wood DA, Ye J, Gurvitch R, Masson JB, Rodés-Cabau J, Osten M, Horlick E, Wendler O, Dumont E, Carere RG, Wijesinghe N, Nietlisbach F, Johnson M, Thompson CR, Moss R, Leipsic J, Munt B, Lichtenstein SV, Cheung A. Transcatheter valve-in-valve implantation for failed bioprosthetic heart valves. *Circulation*. 2010 Apr ;121(16):1848-57.
29. Zahn EM, Hellenbrand WE, Lock JE et al. Implantation of the Melody transcatheter pulmonary valve in patients with a dysfunctional right ventricular outflow tract conduit early result from the U.S. clinical trial. *Journal of the American College of Cardiology*. 2009 Oct; 54(18): 1722-1729.

COMMITTEE APPROVAL:

This Medical Coverage Guideline (MCG) was approved by the Florida Blue Medical Policy and Coverage Committee on 07/25/24.

GUIDELINE UPDATE INFORMATION:

08/15/13	New Medical Coverage Guideline.
08/15/14	Scheduled review: position statement unchanged, references updated.
11/01/15	Revision: ICD-9 Codes deleted.
01/01/16	Annual HCPCS code update. Deleted 0262T. Added 33477.

09/15/18	Revised position statement; added transcatheter pulmonary valve implantation for members with congenital heart disease and current right ventricular outflow tract obstruction or regurgitation, including indications. Deleted ICD-10 codes. Updated description and references.
09/15/20	Review; no change to position statement. Updated references.
10/15/22	Review; revised position statement. Updated references.
05/25/23	Update to Program Exceptions section.
05/15/24	Position statements maintained. Revised program exception.
08/15/24	Review; no change to position statement. Updated references.